๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma

โœ Scribed by Masafumi Ikeda; Takuji Okusaka; Hideki Ueno; Yoriko Takezako; Chigusa Morizane

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
97 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of 5-fluorouracil, interf
Phase II trial of 5-fluorouracil, interferon-ฮฑ and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
โœ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB ๐Ÿ‘ 1 views

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d

Phase II trial of tamoxifen, etoposide,
Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma
โœ Suzanne D. Conzen; Peter A. Kaufman; Christine Arvizu; Paul LeMarbre; L. Herbert ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 554 KB

## BACKGROUND. Based on previous data demonstrating a potentially synergistic interaction between tamoxifen and cisplatin in metastatic melanoma therapy, a Phase I1 study was performed to assess the activity of tamoxifen, etoposide, mitoxantrone, and cisplatin (TEMP) in patients with metastatic br

A phase II trial of methotrexate, cispla
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma
โœ William K. Oh; Judith Manola; Jerome P. Richie; Kevin R. Loughlin; Philip W. Kan ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB ๐Ÿ‘ 2 views

The current treatment of advanced urothelial carcinoma generates high response rates but is associated with poor overall survival. The current study evaluated the efficacy and toxicity of a new combination of active drugs in the treatment of urothelial carcinoma. ## METHODS. Twenty-four patients